eli lilly gip glp-1 Lilly's retatrutide, a GIP/GLP-1/glucagon triple agonist, met Phase 3 endpoints, delivering 28.3% weight loss over 80 weeks in TRIUMPH-1. # EliLilly #Retatrutide #GLP1 #GIP #Glucagon #ObesityTreatment #Phase3 #TRIUMPH1 #WeightLossDrugs GLP4 coming out Eli Lilly
Description
Integrative medicine is a new concept that combines conventional treatment with evidence-based complementary therapies
Adipokines (e.g., leptin and adiponectin) are regulated by DPP-4 and may influence bone remodeling and energy metabolism in a paracrine manner
The pouches
Methods We conducted a systematic review of studies from PubMed, Embase, and Cochrane databases (until November 2024), as well as relevant abstracts from Digestive Disease Week (DDW) 2024 and American College of Gastroenterology (ACG) 2024 to assess the impact of GLP-1 receptor agonists (GLP-1 RAs) on EGD
Anton Moskalenko, DDS, play a key role in managing any potential side effects
